GH Research PLC (GHRS)
11.40
-0.98
(-7.96%)
USD |
NASDAQ |
May 02, 15:53
GH Research Cash and Short Term Investments (Quarterly): 161.56M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 161.56M |
| September 30, 2023 | 161.28M |
| June 30, 2023 | 165.38M |
| March 31, 2023 | 162.82M |
| December 31, 2022 | 165.96M |
| September 30, 2022 | 256.94M |
| June 30, 2022 | 265.38M |
| Date | Value |
|---|---|
| March 31, 2022 | 270.75M |
| December 31, 2021 | 276.78M |
| September 30, 2021 | 280.74M |
| June 30, 2021 | 292.62M |
| March 31, 2021 | 4.576M |
| December 31, 2020 | 5.895M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
4.576M
Minimum
Mar 2021
292.62M
Maximum
Jun 2021
190.05M
Average
165.96M
Median
Dec 2022
Cash and Short Term Investments (Quarterly) Benchmarks
| Amarin Corp PLC | 320.66M |
| Jazz Pharmaceuticals PLC | 1.626B |
| Prothena Corp PLC | 618.83M |
| Iterum Therapeutics PLC | 23.93M |
| Mural Oncology PLC | 270.85M |